A Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung Cancer

Launched by HUNAN PROVINCE TUMOR HOSPITAL · Dec 23, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how patients with advanced lung cancer, specifically those with a certain genetic change called a MET mutation, are being treated in real-life settings. The main goal is to collect information about the different treatment approaches and their effectiveness in people who have this type of lung cancer. The study will include adults aged 18 and older who have been diagnosed with advanced non-small cell lung cancer (NSCLC) that cannot be surgically removed. Participants will need to provide consent and have their tumor tissue tested for genetic changes before enrolling.

If you join this study, you won’t receive any new treatments; instead, your existing treatment plan will continue as usual. Researchers will gather information about your health and treatment every three months to better understand how well current therapies are working for patients like you. Importantly, there are no exclusions based on health conditions, making this trial accessible to a wide range of patients with advanced lung cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients must be ≥18 years of age.
• • 2. Provision of fully informed consent prior to any study specific procedures.
• • 3. Histologically or cytologically confirmed, unresectable stage IIIB/IIIC or stage IV NSCLC.
• • 4. Genetic variants of tumor tissue detected by NGS.
• Exclusion Criteria:
• • None.